Gene may determine how well Weight-Loss drugs work
NCT ID NCT06069622
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a person's genes (specifically the CAV-1 gene) affect how well GLP-1 weight-loss drugs lower blood pressure and body weight. Researchers will enroll 30 overweight or obese adults to take a GLP-1 drug and measure changes. The goal is to learn why some people respond better than others, which could lead to more personalized treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT AND OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Brigham and Women's Hospital
RECRUITINGBoston, Massachusetts, 02115, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Daily pill could offer new hope for weight loss in east asian adults
- Can a Boron-Based pill tame obesity and blood sugar?
- Citrus flavonoid hesperidin put to the test as a brain booster for overweight adults
- Could dimming lights and early dinners boost insulin sensitivity?
- Extra sleep may boost insulin sensitivity and cut heart risk
- Can changing when and what you eat trick your body into making less fat?